Additionally, polymorphism might be potentially conducive to treatment choice for patients, and Wang et al. reported that the gefitinib-associated EGFR mutations were rarely occurred in adenocarcinoma of esophagogastric junction [29]. This evidence concerns the gene EGFR and adenocarcinoma.